{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:22:04Z","timestamp":1793996524356,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41386-019-0333-8","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T17:03:44Z","timestamp":1549472624000},"page":"1398-1405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder"],"prefix":"10.1038","volume":"44","author":[{"given":"Charlotte Marie","family":"Pretzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Freyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0258-5917","authenticated-orcid":false,"given":"Bogdan","family":"Voinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lythgoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Horder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Andreina","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-8038","authenticated-orcid":false,"given":"Robert","family":"Wichers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ajram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glynis","family":"Ivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Heasman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A. E.","family":"Edden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G. M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e1inne M.","family":"McAlonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"333_CR1","doi-asserted-by":"crossref","unstructured":"Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. Mmwr-Morbid Mortal W. 2018;67:1\u201323.","DOI":"10.15585\/mmwr.ss6706a1"},{"key":"333_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1474-4422(02)00160-6","volume":"1","author":"R Tuchman","year":"2002","unstructured":"Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002;1:352\u20138.","journal-title":"Lancet Neurol"},{"key":"333_CR3","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s10803-012-1679-5","volume":"43","author":"G Joshi","year":"2013","unstructured":"Joshi G, Wozniak J, Petty C, Martelon MK, Fried R, Bolfek A, et al. Psychiatric comorbidity and functioning in a clinically referred population of adults with autism spectrum disorders: a comparative study. J Autism Dev Disord. 2013;43:1314\u201325.","journal-title":"J Autism Dev Disord"},{"key":"333_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1192\/bjp.bp.114.160192","volume":"208","author":"T Hirvikoski","year":"2016","unstructured":"Hirvikoski T, Mittendorfer-Rutz E, Boman M, Larsson H, Lichtenstein P, Bolte S. Premature mortality in autism spectrum disorder. Br J Psychiatry. 2016;208:232\u20138.","journal-title":"Br J Psychiatry"},{"key":"333_CR5","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/jps.2600610930","volume":"61","author":"PS Fetterman","year":"1972","unstructured":"Fetterman PS, Turner CE. Constituents of Cannabis sativa L. I. Propyl homologs of cannabinoids from an Indian variant. J Pharm Sci. 1972;61:1476\u20137.","journal-title":"J Pharm Sci"},{"key":"333_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","volume":"10","author":"DT Wade","year":"2004","unstructured":"Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434\u201341.","journal-title":"Mult Scler"},{"key":"333_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","volume":"65","author":"DJ Rog","year":"2005","unstructured":"Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812\u20139.","journal-title":"Neurology"},{"key":"333_CR8","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","volume":"362","author":"J Zajicek","year":"2003","unstructured":"Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517\u201326.","journal-title":"Lancet"},{"key":"333_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36:1219\u201326.","journal-title":"Neuropsychopharmacology"},{"key":"333_CR10","first-page":"176","volume":"22","author":"CT Campbell","year":"2017","unstructured":"Campbell CT, Phillips MS, Manasco K. Cannabinoids in Pediatrics. J Pediatr Pharmacol Ther. 2017;22:176\u201385.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"333_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270\u20138.","journal-title":"Lancet Neurol"},{"key":"333_CR12","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376:2011\u201320.","journal-title":"N Engl J Med"},{"key":"333_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085\u201396.","journal-title":"Lancet"},{"key":"333_CR14","doi-asserted-by":"publisher","first-page":"11229","DOI":"10.1073\/pnas.1711351114","volume":"114","author":"JS Kaplan","year":"2017","unstructured":"Kaplan JS, Stella N, Catterall WA, Westenbroek RE. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA 2017;114:11229\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mcn.2008.09.001","volume":"40","author":"A Musella","year":"2009","unstructured":"Musella A, De Chiara V, Rossi S, Prosperetti C, Bernardi G, Maccarrone M, et al. TRPV1 channels facilitate glutamate transmission in the striatum. Mol Cell Neurosci. 2009;40:89\u201397.","journal-title":"Mol Cell Neurosci"},{"key":"333_CR16","first-page":"1","volume":"1","author":"KW Ho","year":"2012","unstructured":"Ho KW, Ward NJ, Calkins DJ. TRPV1: a stress response protein in the central nervous system. Am J Neurodegener Dis. 2012;1:1\u201314.","journal-title":"Am J Neurodegener Dis"},{"key":"333_CR17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","volume":"14","author":"N Santana","year":"2004","unstructured":"Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex. 2004;14:1100\u20139.","journal-title":"Cereb Cortex"},{"key":"333_CR18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30:1037\u201343.","journal-title":"Neurochem Res"},{"key":"333_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.104","volume":"7","author":"LA Ajram","year":"2017","unstructured":"Ajram LA, Horder J, Mendez MA, Galanopoulos A, Brennan LP, Wichers RH, et al. Shifting brain inhibitory balance and connectivity of the prefrontal cortex of adults with autism spectrum disorder. Transl Psychiatry. 2017;7:e1137.","journal-title":"Transl Psychiatry"},{"key":"333_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-014-0189-0","volume":"11","author":"A El-Ansary","year":"2014","unstructured":"El-Ansary A, Al-Ayadhi L. GABAergic\/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders. J Neuroinflamm. 2014;11:189.","journal-title":"J Neuroinflamm"},{"key":"333_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.53","volume":"3","author":"J Horder","year":"2013","unstructured":"Horder J, Lavender T, Mendez MA, O\u2019Gorman R, Daly E, Craig MC, et al. Reduced subcortical glutamate\/glutamine in adults with autism spectrum disorders: a [(1)H]MRS study. Transl Psychiatry. 2013;3:e279.","journal-title":"Transl Psychiatry"},{"key":"333_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/cap.2014.0112","volume":"25","author":"DM Cochran","year":"2015","unstructured":"Cochran DM, Sikoglu EM, Hodge SM, Edden RA, Foley A, Kennedy DN, et al. Relationship among glutamine, gamma-aminobutyric acid, and social cognition in autism spectrum disorders. J Child Adolesc Psychopharmacol. 2015;25:314\u201322.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"333_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/npp.2014.258","volume":"40","author":"S Bhattacharyya","year":"2015","unstructured":"Bhattacharyya S, Falkenberg I, Martin-Santos R, Atakan Z, Crippa JA, Giampietro V, et al. Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology. 2015;40:1343\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"333_CR24","unstructured":"World Health Organisation. International Statistical Classification of Diseases and Related Health Problems. Geneva, Switzerland 2016."},{"key":"333_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/BF02172145","volume":"24","author":"C Lord","year":"1994","unstructured":"Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659\u201385.","journal-title":"J Autism Dev Disord"},{"key":"333_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/BF02211841","volume":"19","author":"C Lord","year":"1989","unstructured":"Lord C. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord. 1989;19:185\u2013212.","journal-title":"J Autism Dev Disord"},{"key":"333_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J","volume":"11","author":"M Mescher","year":"1998","unstructured":"Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11:266\u201372.","journal-title":"NMR Biomed"},{"key":"333_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/mrm.26091","volume":"77","author":"R Simpson","year":"2017","unstructured":"Simpson R, Devenyi GA, Jezzard P, Hennessy TJ, Near J. Advanced processing and simulation of MRS data using the FID appliance (FID-A)An open source, MATLAB-based toolkit. Magn Reson Med. 2017;77:23\u201333.","journal-title":"Magn Reson Med"},{"key":"333_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.biopsych.2005.03.040","volume":"58","author":"E Hollander","year":"2005","unstructured":"Hollander E, Anagnostou E, Chaplin W, Esposito K, Haznedar MM, Licalzi E, et al. Striatal volume on magnetic resonance imaging and repetitive behaviors in autism. Biol Psychiatry. 2005;58:226\u201332.","journal-title":"Biol Psychiatry"},{"key":"333_CR30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.mri.2004.02.006","volume":"22","author":"ZY Tong","year":"2004","unstructured":"Tong ZY, Yamaki T, Harada K, Houkin K. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn Reson Imaging. 2004;22:735\u201342.","journal-title":"Magn Reson Imaging"},{"key":"333_CR31","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1038\/npp.2016.64","volume":"41","author":"M Schuetze","year":"2016","unstructured":"Schuetze M, Park MT, Cho IY, MacMaster FP, Chakravarty MM, Bray SL. Morphological alterations in the thalamus, striatum, and pallidum in autism spectrum disorder. Neuropsychopharmacology. 2016;41:2627\u201337.","journal-title":"Neuropsychopharmacology"},{"key":"333_CR32","doi-asserted-by":"publisher","first-page":"e38786","DOI":"10.1371\/journal.pone.0038786","volume":"7","author":"A Bejjani","year":"2012","unstructured":"Bejjani A, O\u2019Neill J, Kim JA, Frew AJ, Yee VW, Ly R, et al. Elevated glutamatergic compounds in pregenual anterior cingulate in pediatric autism spectrum disorder demonstrated by 1H MRS and 1H MRSI. PLoS ONE 2012;7:e38786.","journal-title":"PLoS ONE"},{"key":"333_CR33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nrn1763","volume":"6","author":"PJ Conn","year":"2005","unstructured":"Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci. 2005;6:787\u201398.","journal-title":"Nat Rev Neurosci"},{"key":"333_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15292","volume":"8","author":"MC Marrone","year":"2017","unstructured":"Marrone MC, Morabito A, Giustizieri M, Chiurchiu V, Leuti A, Mattioli M, et al. TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. Nat Commun. 2017;8:15292.","journal-title":"Nat Commun"},{"key":"333_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/138920111793937826","volume":"12","author":"F Touska","year":"2011","unstructured":"Touska F, Marsakova L, Teisinger J, Vlachova VA. \u201ccute\u201d desensitization of TRPV1. Curr Pharm Biotechnol. 2011;12:122\u20139.","journal-title":"Curr Pharm Biotechnol"},{"key":"333_CR36","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1073\/pnas.1112345109","volume":"109","author":"J Veenstra-VanderWeele","year":"2012","unstructured":"Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Shah CR, et al. Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc Natl Acad Sci USA 2012;109:5469\u201374.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"333_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bbr.2013.04.043","volume":"249","author":"DM Kerr","year":"2013","unstructured":"Kerr DM, Downey L, Conboy M, Finn DP, Roche M. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res. 2013;249:124\u201332.","journal-title":"Behav Brain Res"},{"key":"333_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00401-006-0176-3","volume":"113","author":"J Yip","year":"2007","unstructured":"Yip J, Soghomonian JJ, Blatt GJ. Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: pathophysiological implications. Acta Neuropathol. 2007;113:559\u201368.","journal-title":"Acta Neuropathol"},{"key":"333_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/sj.mp.4001011","volume":"7","author":"JD Buxbaum","year":"2002","unstructured":"Buxbaum JD, Silverman JM, Smith CJ, Greenberg DA, Kilifarski M, Reichert J, et al. Association between a GABRB3 polymorphism and autism. Mol Psychiatry. 2002;7:311\u20136.","journal-title":"Mol Psychiatry"},{"key":"333_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/syn.21747","volume":"68","author":"JFM Myers","year":"2014","unstructured":"Myers JFM, Evans CJ, Kalk NJ, Edden RAE, Lingford-Hughes AR. Measurement of GABA using J-difference edited H-1-MRS following modulation of synaptic GABA concentration with tiagabine. Synapse. 2014;68:355\u201362.","journal-title":"Synapse"},{"key":"333_CR41","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1113\/jphysiol.2011.216978","volume":"589","author":"CJ Stagg","year":"2011","unstructured":"Stagg CJ, Bestmann S, Constantinescu AO, Moreno LM, Allman C, Mekle R, et al. Relationship between physiological measures of excitability and levels of glutamate and GABA in the human motor cortex. J Physiol-Lond. 2011;589:5845\u201355.","journal-title":"J Physiol-Lond"},{"key":"333_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.124","volume":"2","author":"E Lemonnier","year":"2012","unstructured":"Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry. 2012;2:e202.","journal-title":"Transl Psychiatry"},{"key":"333_CR43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature11356","volume":"489","author":"S Han","year":"2012","unstructured":"Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB, et al. Autistic-like behaviour in Scn1a+\/\u2212 mice and rescue by enhanced GABA-mediated neurotransmission. Nature. 2012;489:385\u201390.","journal-title":"Nature"},{"key":"333_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tins.2005.06.006","volume":"28","author":"JG McHaffie","year":"2005","unstructured":"McHaffie JG, Stanford TR, Stein BE, Coizet W, Redgrave P. Subcortical loops through the basal ganglia. Trends Neurosci. 2005;28:401\u20137.","journal-title":"Trends Neurosci"},{"key":"333_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/archneur.64.1.20","volume":"64","author":"MR DeLong","year":"2007","unstructured":"DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007;64:20\u20134.","journal-title":"Arch Neurol"},{"key":"333_CR46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/155005941004100204","volume":"41","author":"M DeLong","year":"2010","unstructured":"DeLong M, Wichmann T. Changing views of basal ganglia circuits and circuit disorders. Clin EEG Neurosci. 2010;41:61\u20137.","journal-title":"Clin EEG Neurosci"},{"key":"333_CR47","doi-asserted-by":"publisher","first-page":"e67329","DOI":"10.1371\/journal.pone.0067329","volume":"8","author":"S Mueller","year":"2013","unstructured":"Mueller S, Keeser D, Samson AC, Kirsch V, Blautzik J, Grothe M, et al. Convergent findings of altered functional and structural brain connectivity in individuals with high functioning autism: a multimodal MRI study. PLoS ONE 2013;8:e67329.","journal-title":"PLoS ONE"},{"key":"333_CR48","first-page":"408","volume":"9","author":"AM D\u2019Mello","year":"2015","unstructured":"D\u2019Mello AM, Stoodley CJ. Cerebro-cerebellar circuits in autism spectrum disorder. Front Neurosci. 2015;9:408.","journal-title":"Front Neurosci"},{"key":"333_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/scan\/nsn011","volume":"3","author":"DP Kennedy","year":"2008","unstructured":"Kennedy DP, Courchesne E. Functional abnormalities of the default network during self- and other-reflection in autism. Soc Cogn Affect Neurosci. 2008;3:177\u201390.","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"7","key":"333_CR50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.euroneuro.2018.04.004","volume":"28","author":"Oliver Grimm","year":"2018","unstructured":"Grimm O, Loffler M, Kamping S, Hartmann A, Rohleder C, Leweke M, et al. Probing the endocannabinoid system in healthy volunteers: cannabidiol alters fronto-striatal resting-state connectivity. Eur Neuropsychopharmacol. 2018;28:841\u2013849.","journal-title":"European Neuropsychopharmacology"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0333-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:18Z","timestamp":1684616718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-019-0333-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1038\/s41386-019-0333-8","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"18 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}